Previous 10 | Next 10 |
2024-03-06 09:41:52 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals announces registered direct and private placement offering Seeking Alpha’s Quant Rating on Cyclacel Pharmaceuticals Historical earnings data for Cyclacel Pharmaceuticals F...
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximate...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief E...
2024-01-30 09:53:28 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering Seeking Alpha’s Quant Rating on Cyclacel Pharmace...
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the ...
2024-01-19 17:05:04 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering Seeking Alpha’s Quant Rating on Cyclacel Pharmace...
2024-01-09 10:00:06 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and utilities could perform better in 2024 - analyst For further details see: Cyc...
2024-01-09 08:21:38 ET More on Pre-market losers $ stocks. Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering Financial information for Aclarion, Inc. Seek...
2024-01-08 09:33:32 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering For further details see: CYCC regains compliance wit...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. Website:
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...